Live-attenuated vaccines are very effective vaccines used in the prevention of a variety of diseases including influenza, chickenpox, measles, polio and TB. Live-attenuated vaccines can be produced by reverse genetics including RNAi.
Rise in cases of infectious diseases across the globe and ongoing clinical trials by major pharmaceutical players are major factors expected to drive the growth of global live attenuated vaccines market. There is rise in number of inpatients in hospitals suffering from various infectious diseases. According to the World Health Organization, in 2015, tuberculosis accounted for 1.8 million deaths and 10.4 million people were living with the disease. Over 95% deaths due to tuberculosis were in middle- or low-income countries. With the ongoing pandemic situation the government and public players are focused on development of advanced drugs in order to lowering mortality due to deadly virus. Government is spending high in the R&D activities, coupled with focus in infrastructure development to deliver enhance medical care to patents. In 2020, the government of US announced an investment of US$ 1.6 Bn to support pharmaceutical company Novavax in the development of 100 million doses of a Covid-19 vaccine by early 2021. In addition, Finance Minister of India announced US$ 9 Bn funding for vaccine research in the country. The minister clarified the funding will only be for research and development of COVID-19 vaccine.
Major players approach towards introduction of novel vaccines is expected to augment the growth of live attenuated vaccines market. In 2020, Codagenix, Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies partnered with Serum Institute of India with the focus to manufacturing CDX-005, the company's intranasal, live-attenuated vaccine candidate for SARS-CoV-2, the virus that causes COVID-19.
In 2019, Sanofi Pasteur Inc., a drug manufacturing company received approval from FDA for Dengvaxia (Dengue Tetravalent Vaccine, Live) for the prevention of dengue disease caused by serotypes 1 – 4 of the virus in individuals 9 through 16 years of age in the US. This is expected to help the company to enhance the product offering and increase the revenue share.
Increasing consumer inclination towards patient specific treatment and government focus on development hospital infrastructure are factors expected to boost the growth of live attenuated vaccines market. Factors such as high cost associated to R&D activities and stringent government regulations related to product approval are expected to hamper the growth of global live attenuated vaccines market. In addition, lack of developed infrastructure for R&D activities in developing countries and low funding are factors expected to challenge the growth of target market. However, increasing investment by major players for development of innovative drugs and increasing healthcare spending by the developing government in order to deliver better care to patients are factors expected to create new opportunities for players operating in the live attenuated vaccines market over the forecast period. In addition, major player’s inclination towards emerging economies due to easy availability of raw material and low cost labor is expected to support the revenue transaction of target market.
Segment Analysis by Region
The market in North America is expected to account for major revenue share in the global live attenuated vaccines market due to rising number of patients suffering from infectious diseases. Increasing government spending on development of healthcare infrastructure and increasing clinical trials by major pharmaceutical manufacturers are factors expected to boost the growth of target market. In addition, increasing acquisition activities by major players in order to enhance the business and increase the revenue share are factors expected to augment the growth of live attenuated vaccines regional market.
The global live attenuated vaccines market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.
Live Attenuated Vaccines Market Segment Analysis, 2019
The global live attenuated vaccines market is segmented into product type, development, indications, route of administration, distribution channel, and end use. The product type segment is divided into bacterial and viral. Among product type, the viral segment is expected to witness faster growth in the target market. The distribution channel segment is bifurcated into hospital pharmacies and retail pharmacies. Among distribution channel, the hospital pharmacies segment is expected to account for major revenue share in the global live attenuated vaccines market. The players profiled in the report are Sanofi, Emergent BioSolutions Inc, GlaxoSmithKline plc, Daiichi Sankyo Company, Limited, AstraZeneca, Biological E, SutroVax Inc, Polymun Scientific, Boehringer Ingelheim International GmbH, Merck & Co., Inc, and Sanaria.
Market By Product Type
Market By Development
Market By Indication
Market By Route of Administration
Market By Distribution Channel
Market By End Use
Market By Geography
• Rest of Europe
• South Korea
• Rest of Asia-Pacific
• Rest of Latin America
Middle East & Africa
• South Africa
• Rest of Middle East & Africa
Rise in cases of infectious diseases across the globe and ongoing clinical trials by major pharmaceutical players are major factors expected to drive the growth of global live attenuated vaccines market.
In product type the viral segment is growing at faster pace.
In the global market the Asia Pacific region is expected to grow faster.
Some of the players considered in the report scope are Sanofi, Emergent BioSolutions Inc, GlaxoSmithKline plc, Daiichi Sankyo Company, Limited, and AstraZeneca.
The North America is expected to account for major revenue share in the global market.
In end use the hospital segment is growing at faster pace.
Factors such as high cost associated to R&D activities and stringent government regulations related to product approval are expected to hamper the growth of global live attenuated vaccines market.